Los Angeles Capital Management LLC Purchases New Shares in Axon Enterprise, Inc. (NASDAQ:AXON)

Los Angeles Capital Management LLC purchased a new position in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 55,250 shares of the biotechnology company's stock, valued at approximately $14,273,000. Los Angeles Capital Management LLC owned approximately 0.07% of Axon Enterprise as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Sands Capital Management LLC increased its holdings in Axon Enterprise by 31.1% in the third quarter. Sands Capital Management LLC now owns 2,612,305 shares of the biotechnology company's stock valued at $519,823,000 after purchasing an additional 619,179 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Axon Enterprise by 3.3% in the 3rd quarter. Wellington Management Group LLP now owns 1,956,022 shares of the biotechnology company's stock valued at $389,229,000 after acquiring an additional 62,324 shares during the period. Bank of New York Mellon Corp raised its position in shares of Axon Enterprise by 28.3% in the 3rd quarter. Bank of New York Mellon Corp now owns 726,400 shares of the biotechnology company's stock valued at $144,546,000 after acquiring an additional 160,359 shares during the period. Westfield Capital Management Co. LP boosted its stake in Axon Enterprise by 184.3% during the 3rd quarter. Westfield Capital Management Co. LP now owns 696,193 shares of the biotechnology company's stock worth $138,535,000 after acquiring an additional 451,350 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in Axon Enterprise by 3.1% during the third quarter. Northern Trust Corp now owns 631,212 shares of the biotechnology company's stock valued at $125,605,000 after purchasing an additional 19,068 shares during the period. Institutional investors own 79.08% of the company's stock.

Analyst Upgrades and Downgrades

AXON has been the topic of a number of research analyst reports. Needham & Company LLC restated a "buy" rating and set a $400.00 price objective on shares of Axon Enterprise in a report on Wednesday, April 24th. Robert W. Baird upped their price objective on Axon Enterprise from $260.00 to $300.00 and gave the stock an "outperform" rating in a research report on Thursday, February 22nd. StockNews.com downgraded Axon Enterprise from a "buy" rating to a "hold" rating in a report on Thursday, March 14th. JMP Securities boosted their target price on Axon Enterprise from $320.00 to $375.00 and gave the company a "market outperform" rating in a research note on Wednesday. Finally, JPMorgan Chase & Co. raised their price target on shares of Axon Enterprise from $330.00 to $365.00 and gave the stock an "overweight" rating in a research note on Thursday, April 11th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to MarketBeat.com, Axon Enterprise currently has an average rating of "Moderate Buy" and an average target price of $323.09.

Axon Enterprise Stock Performance

Shares of NASDAQ AXON traded up $1.80 during trading hours on Friday, reaching $318.55. 279,175 shares of the stock were exchanged, compared to its average volume of 468,981. The stock's fifty day simple moving average is $308.83 and its 200 day simple moving average is $265.28. The firm has a market capitalization of $24.04 billion, a price-to-earnings ratio of 138.50 and a beta of 0.91. Axon Enterprise, Inc. has a 52 week low of $175.37 and a 52 week high of $329.87. The company has a debt-to-equity ratio of 0.42, a quick ratio of 2.66 and a current ratio of 3.00.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its earnings results on Tuesday, February 27th. The biotechnology company reported $0.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.48 by $0.29. The firm had revenue of $432.14 million for the quarter, compared to analyst estimates of $418.97 million. Axon Enterprise had a net margin of 11.14% and a return on equity of 14.11%. Sell-side analysts predict that Axon Enterprise, Inc. will post 2.44 EPS for the current year.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.